Nurix Therapeutics, Inc.NRIXEarnings & Financial Report
Nasdaq
NRIX Q4 2025 Key Financial Metrics
Revenue
$13.6M
Gross Profit
N/A
Operating Profit
$-83.1M
Net Profit
$-78.2M
Gross Margin
N/A
Operating Margin
-612.0%
Net Margin
-576.1%
YoY Growth
2.2%
EPS
$-0.83
Financial Flow
Nurix Therapeutics, Inc. Q4 2025 Financial Summary
Nurix Therapeutics, Inc. reported revenue of $13.6M for Q4 2025, with a net profit of $-78.2M (-576.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $13.6M |
|---|---|
| Net Profit | $-78.2M |
| Gross Margin | N/A |
| Operating Margin | -612.0% |
| Report Period | Q4 2025 |
Nurix Therapeutics, Inc. Annual Revenue by Year
Nurix Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $84.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $84.0M |
| 2024 | $54.5M |
| 2023 | $77.0M |
| 2022 | $38.6M |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.6M | $12.1M | $12.6M | $13.3M | $18.5M | $44.1M | $7.9M | $13.6M |
| YoY Growth | 30.7% | -60.6% | -31.8% | -12.4% | 11.3% | 264.3% | -37.3% | 2.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $312.7M | $511.0M | $513.6M | $669.3M | $615.0M | $591.6M | $522.5M | $688.1M |
| Liabilities | $143.9M | $140.3M | $136.7M | $142.3M | $134.1M | $144.0M | $150.2M | $149.4M |
| Equity | $168.7M | $370.7M | $376.9M | $527.0M | $480.9M | $447.6M | $372.3M | $538.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-42.0M | $-39.7M | $-42.2M | $-48.8M | $-61.1M | $-63.2M | $-57.4M | $-67.8M |